FP 802
Alternative Names: FP-802Latest Information Update: 06 Aug 2024
At a glance
- Originator FundaMental Pharma
- Class Neuroprotectants; Small molecules
- Mechanism of Action NMDA receptor antagonists; TRPM4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
- Research Alzheimer's disease; Huntington's disease
Most Recent Events
- 01 Aug 2024 Early research in Alzheimer's disease in Germany (unspecified route) before August 2024 (FundaMental Pharma pipeline, August 2024)
- 01 Aug 2024 Early research in Huntington's disease in Germany (unspecified route) before August 2024 (FundaMental Pharma pipeline, August 2024)
- 07 Feb 2024 Preclinical trials in Amyotrophic lateral sclerosis in Germany (unspecified route), prior to February 2024